INBRX-106 is a monoclonal antibody commercialized by Inhibrx, with a leading Phase I program in Adenocarcinoma Of The Gastroesophageal Junction. According to Globaldata, it is involved in 4 clinical trials, of which 3 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of INBRX-106’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for INBRX-106 is expected to reach an annual total of $34 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
INBRX-106 is under development for the treatment of solid tumors including non-small cell lung cancer, uveal melanoma, esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, nasopharyngeal cancer, renal cell carcinoma, nasopharyngeal cancer, cervical cancer, gastrointestinal tumor, urothelial (transitional) cell carcinoma, triple-negative breast cancer, small cell lung cancer and hematological malignancies. The drug candidate is an optimized, single domain antibody (sdAb)-based hexavalent agonist of OX40.The drug candidate is a multivalent constitutive agonist. It acts by targeting the OX40 ligand. The drug candidate is developed based on a single domain antibody (sdAb) platform.
Inhibrx is a biotechnology company that discovers and develops biologic therapeutics for the treatment of cancer and infectious diseases. It is investigating INBRX-101, a recombinant human AAT-Fc fusion protein candidate for the treatment of AATD (alpha-1 antitrypsin deficiency); INBRX-109, an engineered tetravalent sdAb-based therapeutic candidate to treat cancer by activating DR5 (death receptor 5). The company is also evaluating INBRX-106 program against advanced or metastatic solid tumors; and INBRX-105 therapeutic candidate targeting patients with programmed death-ligand 1 (PD-L1) expressing tumors. It utilizes its proprietary sdAb (single-domain antibody) platform to develop biotherapeutics that interface with the biology of each target antigen by focusing on immune activation and mediating enhanced signaling. Inhibrx is headquartered in La Jolla, California, the US.
The company reported revenues of (US Dollars) US$7.2 million for the fiscal year ended December 2021 (FY2021), a decrease of 43.9% over FY2020. The operating loss of the company was US$76.6 million in FY2021, compared to an operating loss of US$67.4 million in FY2020. The net loss of the company was US$81.8 million in FY2021, compared to a net loss of US$76.1 million in FY2020. The company reported revenues of US$0.3 million for the third quarter ended September 2022, a decrease of 60.9% over the previous quarter.
For a complete picture of INBRX-106’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.